Reneo Pharmaceuticals (RPHM)
(Delayed Data from NSDQ)
$1.48 USD
-0.03 (-1.99%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $1.49 +0.01 (0.68%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
RPHM 1.48 -0.03(-1.99%)
Will RPHM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RPHM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RPHM
Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study
RPHM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for RPHM
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
Reneo Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Buying
Mitchell Kapoor’s Hold Rating on Reneo Pharmaceuticals Amid OnKure Merger and Oncology Pipeline Potential
RPHM Alert: Monsey Firm of Wohl & Fruchter Investigating Proposed Merger of Reneo Pharmaceuticals With OnKure